Article
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
International journal of molecular sciences - 31 Dec 2014
Ulivi Paola, Delmonte Angelo, Chiadini Elisa, Calistri Daniele, Papi Maximilian, Mariotti Marita, Verlicchi Alberto, Ragazzini Angela, Capelli Laura, Gamboni Alessandro, Puccetti Maurizio, Dubini Alessandra, Burgio Marco Angelo, Casanova Claudia, Crinò Lucio, Amadori Dino, Dazzi Claudio
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) patients respond to TKI, with unknown molecular mechanisms of sensitivity. We considered a case series of 34 EGFR wt NSCLC patients responsive to erlotinib after at least one line of therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.